WHO ICTRP trial
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in…
NL-OMON49041 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON49041 |
|---|---|
| Public title | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk |
| Scientific title | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk - COSMIC-313 |
| Primary sponsor | Exelixis Inc. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Argentina;Australia;Austria;Brazil;Canada;Chile;Czechia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea (the Republic of);Mexico;Netherlands;New Zealand;Poland;Singapore;Spain;Taiwan… |
| Conditions | Hypernephroma Renal Cell Cancer;10038364;Hypernephroma;Renal Cell Cancer |
| Interventions | Subjects who meet all study eligibility criteria will be randomly assigned in a 1:1 fashion to receive double-blinded study treatment as follows: Experimental arm: Cabozantinib (40 mg oral, once daily [qd]) + nivolumab (3 mg/kg infusion… |
| Registration date | Mar 16, 2021 |
| Target size | 15 |
| Secondary IDs | 2018-004567-31;NL70854.018.19 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: